English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, July 7, 2023
エーザイとバイオジェン・インク、「LEQEMBI(R)」(レカネマブ)がアルツハイマー病治療薬として米国FDAよりフル承認を取得
Friday, June 30, 2023
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced
Thursday, June 29, 2023
エーザイ、Gates Ventures、Health Data Research UK、LifeArc、およびエジンバラ大学は認知症の課題解決に寄与するデジタル・ソリューション開発をめざす共同研究「NEURii」を開始
Thursday, June 22, 2023
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City
エーザイ、東京都文京区の2023年度認知症検診事業において「のうKNOW(R)」による脳の健康度測定を継続実施
Tuesday, June 8, 2021
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib
Wednesday, June 2, 2021
エーザイ、人事異動(2021年6月1日付)を発表
Monday, May 31, 2021
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
エーザイと伊藤園による認知症との共生と予防に向けた業務提携について
Thursday, May 20, 2021
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575